Aldeyra Therapeutics (ALDX) vs RenovoRx (RNXT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
RenovoRx (RNXT) has outperformed Aldeyra Therapeutics (ALDX) over the past year, gaining 9.9% versus a loss of 83.1%. Over five years, RNXT leads with a -77.8% price change compared with -88.6% for ALDX. RenovoRx is the larger company by market cap ($57.8 million vs $55.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALDX | RNXT |
|---|---|---|
| Share price | $0.9163 | $1.28 |
| Market cap | $55.28M | $57.77M |
| 1-day change | -3.31% | -3.76% |
| YTD return | -81.70% | +58.33% |
| 1-year return | -83.14% | +9.92% |
| 5-year return | -88.64% | -77.76% |
| EPS (TTM) | $-0.38 | $-0.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.93 | $2.59 |
| 52-week low | $0.862 | $0.701 |
| Distance from 52-week high | -84.55% | -50.58% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +620.29% | +457.03% |
| Average volume | 1.18M | 765.87K |
| Shares outstanding | 60.33M | 45.13M |
| Employees | 6 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RNXT has outperformed ALDX by 93.1 percentage points over the past year.
About Aldeyra Therapeutics
ALDX stock →Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About RenovoRx
RNXT stock →RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
ALDX vs RNXT FAQ
Which is bigger, Aldeyra Therapeutics or RenovoRx?
RenovoRx (RNXT) is larger, with a market capitalization of $57.77M compared with $55.28M for Aldeyra Therapeutics (ALDX).
Which stock has performed better over the past year, ALDX or RNXT?
RNXT returned +9.92% over the past 12 months, compared with -83.14% for ALDX (price return, excluding dividends). Past performance does not predict future results.
Are Aldeyra Therapeutics and RenovoRx in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.